NCT06609525View on ClinicalTrials.gov

Comparing Efficacy and Safety of CTO0303 in Pediatric Subjects

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

May 9, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

March 1, 2025

Conditions
Pupillary Dilation Effect During Cycloplegic Refraction
Interventions
DRUG

CTO0303-A

eye drop, 1 drop 3 times (every 5 minutes) a day

DRUG

CTO0303-B

eye drop, 1 drop 3 times (every 5 minutes) a day

DRUG

CTO0303-C

eye drop, 1 drop 3 times (every 5 minutes) a day

Trial Locations (1)

21565

RECRUITING

Gachon University Gil Medical Center, Incheon

All Listed Sponsors
lead

Taejoon Pharmaceutical Co., Ltd.

INDUSTRY